Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2008

View Archived Issues

Recent patents describe novel antidiabetic agents

New antiobesity agents described in recent Schering-Plough patent

Recent AstraZeneca and Abbott patents report novel analgesic agents

Shire reports progress of third quarter

Light Sciences Oncology completes enrollment in phase III clinical trial of Litx in HCC

Roche to acquire Memory Pharmaceuticals under definitive merger agreement

H. Lundbeck commences phase II trials for Lu-AE-58054

Valeant reports encouraging 48-week results from phase IIb clinical trial of taribavirin

Protox reports positive results from phase II study of PRX-302 in BPH

Arana commences phase II ART-621 trial in rheumatoid arthritis

FDA issues complete response letter to Johnson & Johnson for ceftobiprole

Amorfix completes ALS drug discovery program with third milestone

MorphoSys and Galapagos to co-develop novel antibodies in bone and joint disease

Pharming presents positive results from phase I Prodarsan study

Provectus enrolls half of patient population in phase II PV-10 melanoma trial

Phase I and preclinical results for anti-HCV agent ANA-598 reported

Japan approves additional indication for Lilly's Gemzar in urothelial cancer

Australian TGA grants orphan drug status to DOR BioPharma's orBec for GI GVHD

Shionogi receives Japanese approval for additional indication for Flomox in adults

Anxiolytic and analgesic profile of NeuroSearch's novel GABA-A receptor positive modulator

Novel promising approach for treating diabetes discovered with JNK inhibition

FDA grants full approval to Pfizer's CCR5 antagonist Selzentry for HIV

Abbott's V1b vasopressin antagonists, effective in models of anxiety and depression

Anti-VEGF agents improve retinopathy of prematurity

Antihypertensive efficacy seen with PS-433540 in double-blind trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...